CN1565548A - Chinese drugs for treatment of coronary heart disease and angina pectoris - Google Patents
Chinese drugs for treatment of coronary heart disease and angina pectoris Download PDFInfo
- Publication number
- CN1565548A CN1565548A CN 03135223 CN03135223A CN1565548A CN 1565548 A CN1565548 A CN 1565548A CN 03135223 CN03135223 CN 03135223 CN 03135223 A CN03135223 A CN 03135223A CN 1565548 A CN1565548 A CN 1565548A
- Authority
- CN
- China
- Prior art keywords
- parts
- angina pectoris
- treatment
- group
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010002383 Angina Pectoris Diseases 0.000 title claims description 40
- 238000011282 treatment Methods 0.000 title claims description 31
- 208000029078 coronary artery disease Diseases 0.000 title abstract description 7
- 239000003390 Chinese drug Substances 0.000 title 1
- 241000218176 Corydalis Species 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 37
- 239000007788 liquid Substances 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 11
- 241000628997 Flos Species 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 4
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 241000234653 Cyperus Species 0.000 abstract 1
- 241000244365 Ligusticum sinense Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 210000003296 saliva Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 40
- 238000012360 testing method Methods 0.000 description 36
- 239000008280 blood Substances 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 29
- 210000003734 kidney Anatomy 0.000 description 17
- 230000001737 promoting effect Effects 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 230000017531 blood circulation Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 206010008479 Chest Pain Diseases 0.000 description 14
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 14
- 229960003711 glyceryl trinitrate Drugs 0.000 description 14
- 239000000006 Nitroglycerin Substances 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 208000011580 syndromic disease Diseases 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 239000000341 volatile oil Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 6
- 238000012109 statistical procedure Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 208000009205 Tinnitus Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000004134 energy conservation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 206010029410 night sweats Diseases 0.000 description 3
- 230000036565 night sweats Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 239000008899 fufang danshen Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000003119 painkilling effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000009465 diaoxinxuekang Substances 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 229940093252 sorbitrate Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000009982 suxiao jiuxinwan Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a prepared traditional Chinese medicinal preparation for treating coronary heart disease, which is prepared from the Chinese medicinal herbs including root of red rooted saliva, rhizome of Sichuan lovage, radix paeoniae rubrathe, corydalis tuber, cyperus tuber, fleece-flower root, safflower, and wolfberry fruit.
Description
Technical field: the invention belongs to Chinese medicine and preparation field thereof, specifically is a kind of Chinese medicine for the treatment of angina pectoris.
Background technology: along with the development of society, the improving constantly of the progress of material progress and medical science level, the disease of many harm people's life health has obtained effective control.Yet all multifactor existence such as the generally raising in people's life-span and smoking, high fat diet, obesity, the sickness rate of cardiovascular disease rises relatively, coronary heart disease especially, and the angina pectoris sickness rate is higher, hazardness is bigger, and the serious life and health that is threatening people.Many with blood circulation promoting and blood stasis dispelling in the new Chinese medicine of the treatment angina pectoris that the Ministry of Public Health approval is gone on the market in recent years, the regulating QI to relieve pain therapy is main, as DIAOXINXUE KANG, Radix Salviae Miltiorrhizae oral liquid, FUFANG DANSHEN JIAONANG, XINTONGKOU PIAN, BUXINQI KOUFUYE, taste the heart-yin oral liquid, QI invigorating oral liquid or the like, and clinical research shows that heart deficiency of the kidney yin is year high common etiology and pathogenesis of people, singly executing promoting blood circulation by removing blood stasis is in fear of just hindering, and if with nourishing kidney nourish heart Yu among, both anti-fraud of just hindering, can strengthen cardiorenal function again, more help blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain.
The objective of the invention is to can overcome the defective of prior art function singleness, but realize both blood circulation promoting and blood stasis dispelling for people provide a kind of viewpoint that meets differentiation of tcm, but the Chinese medicine of the treatment angina pectoris of nourishing heart and kidney again.
The objective of the invention is to realize by following technical proposals.
Summary of the invention: the present invention treats the Chinese medicine of angina pectoris, it is characterized in that the raw material that it is mainly filled a prescription by following weight: 60～180 parts of Radix Salviae Miltiorrhizaes, 20～60 parts of Rhizoma Chuanxiongs, 20～60 parts of Radix Paeoniae Rubra, 20～60 parts of Rhizoma Corydalis, 20～60 parts of Rhizoma Cyperis, 20～60 parts of Radix Polygoni Multiflori Preparatas become tablet, granule, pill, capsule or oral liquid through conventional processes.
In the such scheme, can also add 20～60 parts of 20～60 parts on Flos Carthami and/or Fructus Lycii.
Technical scheme of the present invention is just with differentiation of tcm, and organic conception is for instructing, according to the thoracic obstruction (coronary heart disease, angina pectoris) deficiency in origin and excess in superficiality, the characteristics of simulataneous insufficiency and excessive, in conjunction with the clinical experience of clinical observation and development, with blood circulation promoting and blood stasis dispelling, nourishing heart and kidney is the upright topic of method prescription.Radix Salviae Miltiorrhizae is a monarch drug in the side, bitter in the mouth cold nature, GUIXIN, pericardium, Liver Channel, function promoting blood circulation, removing blood stasis and relieving pain, but nourishing blood to tranquillize the mind relieving restlessness again.Rhizoma Chuanxiong, Rhizoma Corydalis, Rhizoma Cyperi are ministerial drug in the side.Rhizoma Chuanxiong, property and flavor of peppery and warm, the hot temperature of loosing is logical, can invigorate blood circulation and can circulation of qi promoting, is the gas medicine in the blood, is used for the pain of qi depression to blood stasis.Rhizoma Corydalis, the arduous temperature of nature and flavor, GUIXIN, liver, spleen channel have activating blood circulation, the merit of stasis-dispelling and pain-killing, the gas promoting the circulation of blood is lived, and general rule is not bitterly.Rhizoma Cyperi, nature and flavor are hot flat, function depressed liver-energy dispersing and QI regulating, menstruction regulating and pain relieving.More than three medicines with the merit of its promoting flow of QI and blood, assist the merit of monarch drug Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, the effect of promoting the circulation of QI to relieve pain is arranged, so be we's ministerial drug again.Flos Carthami, Radix Paeoniae Rubra, Fructus Lycii, Radix Polygoni Multiflori are adjuvant drug in the side.Flos Carthami, the hot temperature of loosing of nature and flavor is logical, goes into the conscience blood system, but promoting blood circulation to restore menstrual flow, stasis-dispelling and pain-killing.Radix Paeoniae Rubra, the nature and flavor hardship is slightly cold, ownership Liver Channel, but clearing away heat and cooling blood, eliminating stasis to stop pain.Flos Carthami, Radix Paeoniae Rubra are with its merit of invigorating blood circulation, and assistant helps the energy of monarch-minister drug promoting the circulation of blood blood stasis dispelling, so be adjuvant drug altogether.Fructus Lycii, Gan Pingzhi profit, invigorating the liver and kidney, benefiting essence-blood, empty no matter essence and blood loses, insufficiency of kidney-YANG, all available it.Though be the principal agent of nourishing YIN, the real product that belong to flat nourishing YIN sun.Radix Polygoni Multiflori Preparata, nature and flavor, sweet, puckery, tepor are longer than invigorating the liver and kidney, and benefiting essence-blood, and temperature and not dry are mended and oiliness, are tonic medicine.Product of the present invention has giving consideration to both the incidental and fundamental, the effect of pain relieving benefit numbness, comparing the most outstanding advantage with new Chinese medicine of other treatment angina pectoris is can tonifying kidneys, strengthening heart, nourish heart by the blood circulation promoting and blood stasis dispelling nourishing kidney, at blood sugar lowering, treatment angina pectoris when preventing and treating hyperlipemia, especially to the gerontal patient special effect of coronary heart disease with hypertension, hyperlipemia or diabetes, effect is remarkable.Its function cures mainly and is blood circulation promoting regulates qi, nourishing kidney yin.Be used for hold concurrently deficiency of kidney yin card of angina pectoris qi depression to blood stasis, that disease is seen is uncomfortable in chest, chest pain, cardiopalmus, dizziness, insomnia, tinnitus, soreness of the waist and knees.
Name of product of the present invention is that red rhizome of chuanxiong is promoted blood circulation.Its dosage form can be tablet, granule, pill, capsule, oral liquid.
The invention is further illustrated by the following examples, and the present invention is not limited only to described embodiment.
The specific embodiment:
Embodiment one
Get 120 parts of Radix Salviae Miltiorrhizaes, 40 parts of Rhizoma Chuanxiongs, 42 parts of Radix Paeoniae Rubra, 45 parts of Rhizoma Corydalis, 40 parts of Rhizoma Cyperis, 45 parts of Radix Polygoni Multiflori Preparatas, above-mentioned primary crude drug is mixed, each 100 kilograms of medical materials add the 1000L drinking water approximately, boil after for the first time soaking 30min, decoct three times, each 60～90 minutes, collect volatile oil simultaneously; Above-mentioned gained medicinal liquid is filtered with 200 mesh sieves, concentrates, to relative density 1.08～1.20 clear paste; With half clear paste spray drying powder process wherein, 160～180 ℃ of inlet temperature, 80～100 ℃ of leaving air temps get the clear paste powder; Second half remaining clear paste is made binding agent, is parent nucleus with above-mentioned extract powder, granulates with granulator, and 60～80 ℃ of inlet temperature, 45～70 ℃ of leaving air temps get granule; In granule, add volatile oil, airtight 24 hours, add the proper amount of lubricating agent tabletting, every 0.55g uses the high-efficiency coating machine coating, and 600 bottles of packing, get the tablet finished product by 60 every bottle.
Embodiment two
Get 160 parts of Radix Salviae Miltiorrhizaes, 55 parts of Rhizoma Chuanxiongs, 50 parts of Radix Paeoniae Rubra, 52 parts of Rhizoma Corydalis, 50 parts of Rhizoma Cyperis, 55 parts of Radix Polygoni Multiflori Preparatas, 45 parts on Flos Carthami, 55 parts of Fructus Lycii, above-mentioned primary crude drug is mixed, the per kilogram medical material adds the 10L drinking water approximately, boil after for the first time soaking 35min, decoct three times, each 45～60 minutes, collect volatile oil simultaneously; With the gained medicinal liquid, 200 mesh sieves filter the back and concentrate with the energy-conservation concentrator of triple effect, and being evaporated to relative density is 1.14～1.18, get clear paste; Get half clear paste spray drying powder process wherein, inlet temperature is 160～180 ℃, and leaving air temp gets the clear paste powder for 80～100 ℃, second half remaining clear paste is made binding agent, is parent nucleus with the extract powder, granulates with one-step-granulating method, 60～80 ℃ of inlet temperature, 45～70 ℃ of leaving air temps get granule; Add above-mentioned volatile oil, airtight 24 hours, be distributed into 4000 bags, every bag of 5g gets the granule finished product.
Embodiment three
Get 70 parts of Radix Salviae Miltiorrhizaes, 25 parts of Rhizoma Chuanxiongs, 22 parts of Radix Paeoniae Rubra, 24 parts of Rhizoma Corydalis, 20 parts of Rhizoma Cyperis, 30 parts of Radix Polygoni Multiflori Preparatas, 20 parts on Flos Carthami, 30 parts of Fructus Lycii, be ground into fine powder, sieve, mixing gets fine powder, add an amount of Mel and water system soft material, general ball on general ball machine, cold drying, packing gets the pill product.
Embodiment four
Get 140 parts of Radix Salviae Miltiorrhizaes, 45 parts of Rhizoma Chuanxiongs, 30 parts of Radix Paeoniae Rubra, 25 parts of Rhizoma Corydalis, 28 parts of Rhizoma Cyperis, 35 parts of Radix Polygoni Multiflori Preparatas, above-mentioned primary crude drug is mixed, per 100 kilograms of medical materials add the 1000L drinking water approximately, boil after for the first time soaking 30min, decoct three times, each 45-60 minute, collect volatile oil simultaneously; Gained medicinal liquid 200 mesh sieves filter the back and concentrate with the energy-conservation concentrator of triple effect, one imitates 80 ℃ of temperature, two 70 ℃ of effects, 60 ℃ of triple effects, be evaporated to relative density 1.14～1.18, get clear paste, get half clear paste spray drying powder process wherein, 160～180 ℃ of inlet temperature, 80～100 ℃ of leaving air temps get extract powder; Second half remaining clear paste is made binding agent, is parent nucleus with the extract powder, granulates with one-step-granulating method, and 60～80 ℃ of inlet temperature, 45～70 ℃ of leaving air temps get granule; Add above-mentioned volatile oil, airtight 24 hours, be filled to capsule with capsule filling machine, every 0.5g, bubble-cap, the dress box, 20 in every box gets 2000 box capsule finished products.
Embodiment five
Get 100 parts of Radix Salviae Miltiorrhizaes, 30 parts of Rhizoma Chuanxiongs, 25 parts of Radix Paeoniae Rubra, 25 parts of Rhizoma Corydalis, 25 parts of Rhizoma Cyperis, 38 parts of Radix Polygoni Multiflori Preparatas, 28 parts on Flos Carthami, 40 parts of Fructus Lycii, above-mentioned primary crude drug 100kg, add the 1000L drinking water, boil after for the first time soaking 35min, decoct three times, each 45-60 minute, collect volatile oil simultaneously, get medicinal liquid; Medicinal liquid 200 mesh sieves are filtered the back are concentrated into every 1ml medicinal liquid with the energy-conservation concentrator of triple effect and are equivalent to crude drug 2g, put cold, the remove impurity of adding ethanol precipitate with ethanol, stir evenly, place 24h and filter, filtrate recycling ethanol is to there not being the alcohol flavor, add preparations such as suitable quantity of water and various additives, filter, embedding in the control oral liquid bottle, every bottle of 10ml, sterilization, be distributed into 800 boxes, 6 in every box promptly gets oral liquid.
In addition, also can add any one of Flos Carthami or Fructus Lycii to weight range in the raw material of embodiment one or embodiment four, obtain required product by aforementioned.
Further specify beneficial effect of the present invention below by clinical trial data.
The clinical trial situation of product of the present invention:
Product of the present invention is observed case 60 examples altogether from year March May to 2000 nineteen ninety-five, test group 30 examples wherein, and matched group 30 examples, result show that test group angina pectoris obvious effective rate is 50%, total effective rate is 90%; The electrocardiogram obvious effective rate is 16.7%, and total effective rate is 53.3%; The tcm syndrome obvious effective rate is 46.7%, and total effective rate is 93.3%, compares with matched group, and the P value all＞0.05.
Research purpose
Objective evaluation product of the present invention treatment angina pectoris Chinese medical discrimination belongs to the hold concurrently clinical efficacy of heart deficiency of the kidney yin and to human safety of qi depression to blood stasis.
Physical data
Select to be in hospital and out-patient's 60 examples, wherein test group inpatient 18 examples account for 60.0%, and out-patient's 12 examples account for 40.0%; Matched group inpatient 19 examples account for 63.3%, and out-patient's 11 examples account for 36.7%.At sex, age, the course of disease, the state of an illness and angina pectoris typing, aspects such as symptom all do not have significant difference before test group and the treatment of control group.P＞0.05, two a group case has comparability.
1, sex
Table 1 liang group patient's sex situation (example)
Group example number men and women
Test group 30 9 21
Matched group 30 8 22
Statistical procedures result: X
2=0.08, P＞0.05
2, the age
Table 2 liang group age distribution situation (year)
Group example number～40～50～60～70
Test group 30 133 23
Matched group 30 124 23
Statistical procedures result: X
2=0, P＞0.05
Test group minimal ages 33 years old, maximum 70 years old age, matched group minimal ages 37 years old, maximum 70 years old age.
One, thoracic obstruction angina pectoris weight grade scale
Revise with reference to therapy of combining Chinese and Western medicine angina pectoris in 1979 and arrhythmia forum " angina pectoris and ECG curative effect evaluation criteria ".
1, slight: have than the classical angina outbreak, each persistent period number minute, pain is shown effect 2-3 time at least weekly, or every outbreak 1-3 time, but pain do not weigh, and need suck nitroglycerin sometimes.
2, moderate: for several times typical angina pectoris attacks is arranged every day, and each persistent period number minute was to 10 minutes, and angina pectoris is heavier, generally all needs to suck nitroglycerin.
3, than severe: the classical angina outbreak is arranged repeatedly every day, thereby influence activities of daily living (for example: defecate, wear the clothes etc.).Each outbreak persistent period is longer, need repeatedly suck nitroglycerin.
4, severe: this type of patient's pain attack times and degree, all relatively severe is attached most importance to.
Two, include the case standard in
1, meet angina pectoris diagnosis, tcm diagnosis is the thoracic obstruction, dialectically is the qi depression to blood stasis patient of syndrome of yin deficiency of heart and kidney that holds concurrently.
2, show effect weekly angina pectoris patient more than 2 times.
3, Electrocardioscopy has the patient that ischemic change or exercise electrocardiogram are positive.
4, the age is at 18-70 between year.
Three, test case quantity, ratio and test method
(1) test group: 30 examples
(2) matched group: 30 examples
(3) adopt inpatient and clinic case, wherein inpatient is no less than 60% of total routine number, and clinic case should select interdependence good, the case of may command variable factor.
(4) group technology
1, the ratio of test group and matched group was grasped by 1: 1, selected case by with
The two the region between the heart and the diaphragms of machine are divided into test group and matched group.
2, double-blind method: two pharmaceutically dosage form unanimities make it that outer package is consistent to get final product, and make each big external packing box hold the medicine of 1 course of treatment, and stamp random number in proportion.
Four, Therapeutic Method
(1) treatment group: each 1 bag of product of the present invention, every day 3 times, boiled water is taken after mixing it with water.
(2) matched group: LEMAI KELI (big pharmaceutical factory produces by the West China medical courses in general, lot number: 990401) each 1 bag, every day 3 times, take after mixing it with water by boiled water.
(3) course of treatment: all around.
Inactive all antianginal medicines before the treatment, can only contain nitroglycerine tablets during angina pectoris attacks, in the clinical trial process, if carrying out property of patient's angina pectoris increases the weight of, or when critical situation such as acute myocardial infarction, severe cardiac functional defect or severe arrhythmia occurring, can be by the treatment of combination of Chinese and Western medicine principle, positive treatment, indicate the medicine mediating recipe amount of using that adds, and as rejecting the case statistics.
Five, observation index
(1) health giving quality observation:
1, ordinary circumstance: blood pressure (mmHg), the rhythm of the heart, heart rate.Before test, duration of test end, test back difference observed and recorded weekly.
2, clinical symptoms: chest pain, uncomfortable in chest, cardiopalmus is insomnia, the dose of the number of times of dizziness and tinnitus, night sweat, soreness of the waist and knees and angina pectoris attacks, persistent period, pain degree, nitroglycerin etc.Before test, duration of test end, test back difference observed and recorded weekly.
3, electrocardiogram: the treatment before, the treatment two weekends and the treatment after carry out the Electrocardioscopy record respectively.
4, blood fat: carry out lipid examination (comprising cholesterol, triglyceride, high density lipoprotein) before and after the treatment.
Six, curative effect determinate standard
Efficacy assessment standard mainly is the improvement situation of stopping lapse rate according to angina pectoris, electrocardiogram, clinical syndrome and nitroglycerin, and therapy of combining Chinese and Western medicine angina pectoris with reference to 1979 and arrhythmia forum " angina pectoris and ECG curative effect evaluation criteria " are formulated.
(1) angina cordis symptom criterion of therapeutical effect
1, slight: produce effects: chest pain disappears, or basic the disappearance.
Effectively: the chest pain outbreak obviously alleviates.
Invalid: the chest pain symptom does not have improvement.
Increase the weight of: the chest pain outbreak increases the weight of, and reaches " moderate " above standard.
2, moderate: produce effects: chest pain disappears, or basic the disappearance.
Effectively: chest pain alleviates one-level, reaches slight standard.
Invalid: the chest pain symptom does not have improvement.
Increase the weight of: the chest pain sx reaches " than severe " or with subscript
Accurate.
3, than severe: produce effects: chest pain disappears or is relieved to " slightly " standard.
Effectively: chest pain is relieved to " moderate standard ".
Invalid: the chest pain symptom is preceding identical with treatment.
Increase the weight of: the chest pain outbreak increases the weight of (or reaching " severe " standard).
(2), ECG curative effect evaluation criteria
1, produce effects: electrocardiogram returns to " roughly normal " or reaches " normal ECG ".
2, effective: the S-T section reduces, and more than the treatment back rise 0.05mv, but does not reach normal level, and shoal at the negative T wave that mainly leads (reaching 25% above person), or the T ripple is upright by smooth change.
3, invalid: electrocardiogram is preceding identical with treatment.
4, increase the weight of: treatment back S-T section reduces and increases the weight of, and the T ripple is deepened, or the T ripple is inverted by smooth change.
(3), the tcm syndrome total effects is judged
Judge the tcm syndrome total effects according to integration method.
Produce effects: n 〉=70%
Effectively: 70%＞n 〉=30%
Invalid: n＜30%
(4) nitroglycerin stops lapse rate: do not take the Chinese medicine preparation that other quick-acting coronary dilating medicines such as sorbitrate, nifedipine and SUXIAO JIUXIN WAN, FUFANG DANSHEN DIWAN etc. contain Radix Salviae Miltiorrhizae during angina pectoris attacks.
1, drug withdrawal: withdraw nitroglycerin after the treatment fully.
Decrement: the treatment back preceding nitroglycerin consumption of treatment is reduced more than 50%.
Constant: treatment back nitroglycerin consumption reduces less than 50%.
2, computational methods:
(5) symptom curative effect
1, disappears: transference cure
2, effective: it is individual differential to alleviate 1-2
3, invalid: no change
Seven, the statistical disposition of clinical data
1, ranked data are checked with Ridit
2, enumeration data X 2 test
3, measurement data is checked with t
Result of the test
1, curative effect to treat angina pectoris
The table 3 liang anginal curative effect of group
Group example digital display is imitated the enabledisable total effective rate
Example (%) example (%) example (%)
Test group 30 15 (50.0) 12 (40.0) 3 (10.0) 90%
Matched group 30 12 (40.0) 13 (43.3) 5 (6.7) 88.3%
Statistical procedures is Ridit:U=0.85 P＞0.05 as a result
Two groups of patient's angina pectoriss all have better curative effect, two groups difference nonsignificance.
2, ECG curative effect
The table 4 liang Electrocardiographic curative effect of group
Group example digital display is imitated the enabledisable total effective rate
Example (%) example (%) example (%)
Test group 30 5 (16.7) 11 (36.6) 14 (46.7) 53.3%
Matched group 30 3 (10.0) 11 (36.6) 16 (53.4) 46.6%
Statistical procedures is Ridit:U=0.647 P＞0.05 as a result
Two groups of patient's electrocardiograms all have improvement in various degree, two groups of ECG curative effect difference nonsignificances.
3, nitroglycerin stops lapse rate
Table 5 a liang group nitroglycerin stops lapse rate
The inactive constant lapse rate that stops of decrement of group example number
Example (%) example (%) example (%)
Test group 22 15 (68.2) 6 (27.3) 1 (4.5) 95.4%
Matched group 24 15 (62.5) 6 (25.0) 3 (12.5) 87.5%
Statistical procedures is Ridit:U=0.72 P＞0.05 as a result
Most of patient stops using to subtract and uses nitroglycerin, nitroglycerin to stop difference nonsignificance between two groups of the lapse rates after two groups of patient's medications.
4, tcm syndrome curative effect
(1) comprehensive therapeutic effect of syndrome
Table 6 liang group therapeutic effect of syndrome relatively
Group example digital display is imitated the enabledisable total effective rate
Example (%) example (%) example (%)
Test group 30 14 (46.7) 14 (46.7) 2 (6.7) 93.3%
Matched group 30 13 (43.3) 14 (46.7) 3 (10.0) 90.0%
Statistical procedures is Ridit:U=0.3328 P＞0.05 as a result
Two groups of comprehensive syndromes of patient all have more significantly improves two groups of curative effect difference nonsignificances.
(2) individual event symptom curative effect
Table 7 liang group individual event symptom curative effect relatively
The constant disappearance total effective rate U P that alleviates of group example number
Test group 30 5 10 15 83.3% 0.67＞0.05 uncomfortable in chest
Matched group 30 6 12 12 80.0%
Cardiopalmus test group 15 438 73.3% 0.27＞0.05
Matched group 18 639 66.7%
Night sweat test group 20 659 70.0% 0.98＞0.05
Matched group 21 10 47 52.3%
The test group of being insomnia 18 486 77.0% 0.929＞0.05
Matched group 19 775 63.1%
Dizzy test group 18 468 70.0% 1.13＞0.05
Matched group 21 876 61.9%
Tinnitus test group 20 73 10 65.0% 0.21＞0.05
Matched group 21 759 66.7%
Waist knee joint test group 26 68 12 76.9% 1.49＞0.05
Aching and limp matched group 25 13 39 48.0%
5, blood fat
Does Blood Lipid compare (X before and after the table 8 liang group treatment? ± S)
T p behind the project group example number medicine prodrug
Cholesterol test group 26 5.58 ± 1.56 5.21 ± 0.94 0.409 ± 1.48 1.41＞0.05
Matched group 27 5.45 ± 0.79 5.25 ± 0.73 0.20 ± 0.54 1.89＞0.05
Triglyceride test group 26 1.61 ± 0.93 1.59 ± 0.83 0.062 ± 0.65 0.48＞0.05
Matched group 27 1.62 ± 0.79 1.52 ± 0.67 0.20 ± 0.64 1.652＞0.05
High density test group 26 1.11 ± 0.33 1.18 ± 0.31-0.016 ± 2.16 0.039＞0.05
Lipoprotein matched group 27 1.19 ± 0.33 1.15 ± 0.26 0.04 ± 0.21 0.99＞0.05
Blood fat does not have significant change before and after two groups of patient treatments.
Discuss
1, result of the test shows: it is 50.0% that product particle of the present invention belongs to hold concurrently heart deficiency of the kidney yin patient's angina pectoris obvious effective rate of qi depression to blood stasis to angina pectoris, total effective rate is 90.0%, electrocardiogram obvious effective rate 16.7%, total effective rate 53.3%, compare the difference nonsignificance with matched group, P all＞0.05.Illustrate that this medicine is definite to curative effect to treat angina pectoris.
2, this medicine is 46.7% to the tcm syndrome obvious effective rate, and total effective rate is 93.3%, and the matched group obvious effective rate is 43.3%, and total effective rate is 90.0%, two group of difference nonsignificance, P＞0.05.
But product of the present invention is better than matched group to the effect of symptoms such as tcm syndrome related symptoms night sweat, insomnia, soreness of the waist and knees, does not reach statistical significance, may be less relevant with case load.
3, patients with coronary heart disease mostly is the old people, often with hypertension and diabetes, and among the old people, diabetes, hyperpietic, than many parts patient again with the disease of the deficiency of YIN, so patients with coronary heart disease on stasis of blood resistance heart arteries and veins basis often with to a certain degree heart deficiency of the kidney yin, this medical instrument has blood circulation promoting regulates qi, the effect of nourishing heart and kidney, to angina pectoris, the qi depression to blood stasis heart deficiency of the kidney yin patient determined curative effect of holding concurrently, the pathogenesis that hits also has bigger adaptation population.
4, do not find untoward reaction and toxic and side effects due to this medicine in the process of the test yet.
Conclusion
Result of the test shows: product of the present invention has curative effect preferably to the hold concurrently angina pectoris of heart deficiency of the kidney yin of qi depression to blood stasis, and has no side effect and harmful effect.
Claims (2)
1, a kind of Chinese medicine for the treatment of angina pectoris, it is characterized in that the raw material that it is mainly filled a prescription by following weight: 60～180 parts of Radix Salviae Miltiorrhizaes, 20～60 parts of Rhizoma Chuanxiongs, 20～60 parts of Radix Paeoniae Rubra, 20～60 parts of Rhizoma Corydalis, 20～60 parts of Rhizoma Cyperis, 20～60 parts of Radix Polygoni Multiflori Preparatas are refined into tablet, granule, pill, capsule or oral liquid by each dosage formulation requirement.
2, the Chinese medicine of treatment angina pectoris according to claim 1 is characterized in that also can adding in the described raw material 20～60 parts of 20～60 parts on Flos Carthami and/or Fructus Lycii.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03135223 CN1232283C (en) | 2003-06-18 | 2003-06-18 | Chinese drugs for treatment of coronary heart disease and angina pectoris |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03135223 CN1232283C (en) | 2003-06-18 | 2003-06-18 | Chinese drugs for treatment of coronary heart disease and angina pectoris |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1565548A true CN1565548A (en) | 2005-01-19 |
| CN1232283C CN1232283C (en) | 2005-12-21 |
Family
ID=34470222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03135223 Expired - Lifetime CN1232283C (en) | 2003-06-18 | 2003-06-18 | Chinese drugs for treatment of coronary heart disease and angina pectoris |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1232283C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869689A (en) * | 2010-06-22 | 2010-10-27 | 杨丽华 | External Chinese medicinal composition for treating angina pectoris coronary heart disease |
| CN102697875A (en) * | 2012-06-15 | 2012-10-03 | 李良 | Safflower carthamus traditional Chinese medicine decoction for treating palpitation and preparation method for decoction |
| CN104306615A (en) * | 2014-09-30 | 2015-01-28 | 韩奎 | Medicine for treating coronary heart disease and preparation method of medicine |
| CN105596975A (en) * | 2015-11-12 | 2016-05-25 | 上海市闸北区中医医院 | Traditional Chinese medicine composition used for treating insomnia |
-
2003
- 2003-06-18 CN CN 03135223 patent/CN1232283C/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869689A (en) * | 2010-06-22 | 2010-10-27 | 杨丽华 | External Chinese medicinal composition for treating angina pectoris coronary heart disease |
| CN102697875A (en) * | 2012-06-15 | 2012-10-03 | 李良 | Safflower carthamus traditional Chinese medicine decoction for treating palpitation and preparation method for decoction |
| CN104306615A (en) * | 2014-09-30 | 2015-01-28 | 韩奎 | Medicine for treating coronary heart disease and preparation method of medicine |
| CN105596975A (en) * | 2015-11-12 | 2016-05-25 | 上海市闸北区中医医院 | Traditional Chinese medicine composition used for treating insomnia |
| CN105596975B (en) * | 2015-11-12 | 2018-10-16 | 上海市闸北区中医医院 | A kind of Chinese medicine composition for treating insomnia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1232283C (en) | 2005-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1628786A (en) | Medicine for treating hyperlipemia | |
| CN1915399A (en) | Preparation for treating high blood pressure, high blood fat, obesity, and climacteric syndrome, and preparation method | |
| CN1228074C (en) | Chinese traditional medicine for treating immune hypofunction and disfunction | |
| CN1239183C (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN1709404A (en) | Chinese patent medicine for preventing and treating apoplexia disease, and its production method and use | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1232283C (en) | Chinese drugs for treatment of coronary heart disease and angina pectoris | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1304735A (en) | Medicine for curing chronic colitis | |
| CN1706435A (en) | Chinese medicine composition for treating premenstrual stage stress syndrome an dits prepn process | |
| CN101028325A (en) | Medicinal composition containing sailonggu, and its preparation and quality control | |
| CN1297290C (en) | Medicinal composition for treating coronary heart disease and stenocardia and its preparation method | |
| CN1857495A (en) | Compound chinese preparation for treating pain symptom and its preparing process | |
| CN1237995C (en) | Ripening agent and eliminating agent for abnormal black balliary matter and its preparation method | |
| CN1211111C (en) | Antilipemic Chinese medicine | |
| CN1258372C (en) | Chinese medicinal composition for treating intestine irritable syndrome and its preparing method | |
| CN1162177C (en) | Medicine for curing fatty liver | |
| CN1284589C (en) | Medicine for treating acute brain blood vessel disease and its preparation method | |
| CN101028340A (en) | Medicinal composition containing siegesbeckia orientalis and its preparation | |
| CN1682974A (en) | Chinese medicine preparation for treating acute laryngopharyngitis and its preparing method | |
| CN1222305C (en) | Chinese medicine for treating liver-kidney insufficiency, qi and yin vacuity and its preparation method | |
| CN1539474A (en) | Drug for treating coronary heart disease, angina and preparation method | |
| CN1308023C (en) | Medicine for treating congestion arhythmia and its preparation method | |
| CN101053626A (en) | Traditional Chinese medicine for treating coronary heart disease and angina pectoris and its preparation method | |
| CN1112196C (en) | Medicine for regulating blood fat and reducing plasma fibrin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: CHENGDU ENWEI PHARMACEUTICAL Co.,Ltd. Assignor: Xue Yongxin Contract record no.: 2010510000093 Denomination of invention: Chinese-medicinal Bastian-Bruns agent for treating coronary heart disease and angina cordis and its making method Granted publication date: 20051221 License type: Exclusive License Open date: 20050119 Record date: 20101022 |
|
| ASS | Succession or assignment of patent right |
Owner name: SICHUAN ENWEI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XUE YONGXIN Effective date: 20140808 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610041 CHENGDU, SICHUAN PROVINCE TO: 610207 CHENGDU, SICHUAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140808 Address after: Chengdu City, Sichuan province Shuangliu County 610207 double road three No. 458 Patentee after: SICHUAN ENWEI PHARMACEUTICAL CO.,LTD. Address before: 610041, No. 28, pioneering Road, hi tech Zone, Sichuan, Chengdu Patentee before: Xue Yongxin |
|
| CX01 | Expiry of patent term |
Granted publication date: 20051221 |
|
| CX01 | Expiry of patent term |